Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O'Day SJ. Kim KB, et al. Among authors: cheverton p. J Clin Oncol. 2012 Jan 1;30(1):34-41. doi: 10.1200/JCO.2011.34.6270. Epub 2011 Nov 28. J Clin Oncol. 2012. PMID: 22124101 Free PMC article. Clinical Trial.
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Clamp A, Adams M, Atkinson R, Boven E, Calvert AH, Cervantes A, Ganesan T, Lotz J, Vasey P, Cheverton P, Jayson GC. Clamp A, et al. Among authors: cheverton p. Gynecol Oncol. 2004 Oct;95(1):114-9. doi: 10.1016/j.ygyno.2004.06.047. Gynecol Oncol. 2004. PMID: 15385119 Clinical Trial.
Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
Schöffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R, Satomi M. Schöffski P, et al. Among authors: cheverton p. Ann Oncol. 2004 Apr;15(4):671-9. doi: 10.1093/annonc/mdh141. Ann Oncol. 2004. PMID: 15033678 Free article. Clinical Trial.
A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.
Kuruvilla J, Tzeng CH, Cho SG, Kim SJ, Tang JL, Su Y, Wu J, Vargo R, Cheverton P. Kuruvilla J, et al. Among authors: cheverton p. Bone Marrow Transplant. 2019 Feb;54(2):258-264. doi: 10.1038/s41409-018-0253-y. Epub 2018 Jun 12. Bone Marrow Transplant. 2019. PMID: 29895931 Free PMC article. Clinical Trial.
DX-8951f: summary of phase I clinical trials.
De Jager R, Cheverton P, Tamanoi K, Coyle J, Ducharme M, Sakamoto N, Satomi M, Suzuki M; DX-8931f Investigators. De Jager R, et al. Among authors: cheverton p. Ann N Y Acad Sci. 2000;922:260-73. doi: 10.1111/j.1749-6632.2000.tb07044.x. Ann N Y Acad Sci. 2000. PMID: 11193901 Review.
14 results